Skip to main content
Article thumbnail
Location of Repository

Redefining the role of thiazolidinediones in the management of type 2 diabetes

By Anthony H Barnett

Abstract

There is a need to evaluate oral glucose-lowering agents not only for their value in achieving glycemic control but also for their impact on cardiac risk factor modification. This article reviews the evidence base for the two thiazolinediones currently available, pioglitazone and rosiglitazone. These drugs exert their effects through actions affecting metabolic control, lipid profiles, and the vascular wall. They have been shown to be as efficacious in establishing glycemic control, in both monotherapy and combination therapy regimens, as more traditional oral agents, and may be able to sustain that control in the long term. Both thiazolidinediones have demonstrated favorable effects on markers of cardiovascular disease. Evidence from the large PROactive outcomes study suggests that pioglitazone may exert protective effects in patients with type 2 diabetes and macrovascular disease. Thiazolidinediones are generally well tolerated but they can cause weight gain, induce fluid retention, and may contribute to bone loss in postmenopausal women. The place of thiazolidinediones in the management of type 2 diabetes is well established. The potential for additional benefits in reducing macrovascular risk encourages further long-term study of these agents

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2672454
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care.
    2. (2005). A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract.
    3. (2006). A fi xed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control. Curr Med Res Opin.
    4. (2004). A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med.
    5. (2003). A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther.
    6. (2007). A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vasc Health Risk Manag.
    7. (2002). Accurate assessment of β-cell function: the hyperbolic correction. Diabetes.
    8. Action to Control Cardiovascular Risk in Diabetes Study Group,
    9. AM; for the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) study.
    10. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
    11. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial.
    12. (2004). BH; for the QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care.
    13. (2006). Can thiazolidinediones delay disease progression in type 2 diabetes? Curr Med Res Opin.
    14. (2004). Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract.
    15. (2008). Comparison of fi xed-dose rosiglitazone/metformin combination therapy with sulfonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes.
    16. (2004). Comparison of pioglitazone and metformin effi cacy using homeostasis model assessment. Diabet Med.
    17. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    18. Diabetes drug pioglitazone (Actos): risk of fracture.
    19. (1995). Diabetes Study (UKPDS) Group. UKPDS 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes.
    20. (2006). Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab.
    21. (1998). Effect of intensive blood-glucose control with metformin on complications
    22. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus.
    23. (2006). Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet Med.
    24. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    25. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
    26. Effect of pioglitizone on pancreatic β-cell function and diabetes risk in Hispanic women with gestational diabetes.
    27. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    28. (2006). Effects of pioglitazone on lipid and lipoprotein profi les in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res.
    29. (2006). Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care.
    30. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.
    31. (2008). Fat and beyond: the diverse biology of PPAR-γ. Ann Rev Biochem.
    32. (2004). Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care.
    33. (2008). for Health and Clinical Excellence (NICE). Type 2 diabetes: the management of type 2 diabetes (update). Available from: http://www.nice.org.uk/CG66 (accessed 17
    34. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    35. (2004). for the GLAC Study Group. Sustained effects of pioglitazone vs glibenclamide on insulin sensitivity, glycaemic control, and lipid profi les in patients with Type 2 diabetes. Diabet Med.
    36. (2007). for the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care.
    37. (2005). for the GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care.
    38. for the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial
    39. (2005). for The QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med.
    40. for the QUARTET Study Group. Effi cacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    41. for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis.
    42. (2001). for the Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulintreated type 2 diabetes. Diabetes Care.
    43. (2001). for the Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care.
    44. for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
    45. for the Rosiglitazone Fluid Retention Study Group. Effect of various diuretic treatments on rosiglitazone-induced fl uid retention.
    46. (2005). Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care.
    47. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies
    48. (2006). Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med.
    49. Guvener Demirag N. Rosiglitazone decreases serum bone-specifi c alkaline phosphatase activity in postmenopausal diabetic women.
    50. (2006). Health. Forecasting obesity to 2010. Department of Health,
    51. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care.
    52. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the PIONEER study.
    53. Infl uence of rosiglitizone treatment on β-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
    54. (2006). Initial treatment with rosiglitazone/metformin fi xed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab.
    55. (2001). Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care.
    56. (1998). Intensive bloodglucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications
    57. (1988). Lilly Lecture The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.
    58. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulfonylurea in the treatment of type 2 diabetes.
    59. Long-term effi cacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    60. (2005). Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev.
    61. Macular Edema associated with glitazone.
    62. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.
    63. (2007). Mariz S; for the COM06 Study Investigators. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fi xed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes Technol Ther.
    64. (2009). Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care.
    65. (2002). Metabolic effi cacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res.
    66. (2006). Metformin and pioglitazone: Effectively treating insulin resistance. Curr Med Res Opin.
    67. (2006). Metformin– glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab.
    68. Metformin–pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    69. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells.
    70. (2002). Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism. Biochem Soc Trans.
    71. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
    72. (2007). Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
    73. (2000). Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther.
    74. (2000). Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care.
    75. (2004). Pioglitazone plus a sulfonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diabetes Vasc Dis Res.
    76. (2007). Pioglitazone plus glimepiride: a promising alternative in metabolic control.
    77. (2008). PPAR agonists and cardiovascular disease in diabetes. PPAR Res.
    78. (2000). PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab.
    79. (2005). Prevalence of the metabolic syndrome defi ned by the International Diabetes Federation among adults in the US. Diabetes Care.
    80. (2007). Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    81. REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
    82. (2006). Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Curr Med Res Opin.
    83. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.
    84. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
    85. (2005). Rosiglitazone/metformin fi xed dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24 week, multicenter, randomized, double blind, parallel group study. Clin Ther.
    86. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    87. (2008). Spontaneous resolution of diabetic macular edema after discontinuation of thizolidinediones. Diabet Med.
    88. (2002). Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin type 2 diabetic patients. Diabetes Care.
    89. (2007). The Avandia debate. Diabetes Care.
    90. (2001). The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis.
    91. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus.
    92. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
    93. The relation of insulin resistance syndromes to risk of cardiovascular disease.
    94. The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes–a systematic review.
    95. (1997). The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med.
    96. The role of declining beta cell function in the progression of type 2 diabetes: implications for outcomes and pharmacological management.
    97. (2006). Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonism. Diabetes Vasc Dis Res.
    98. (2007). Thiazolidinediones and their effect on bone metabolism: a review. Can J Diabetes.
    99. (2007). Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab.
    100. (2007). Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.